Medpace Holdings (MEDP) Price to Sales (2016 - 2026)

Medpace Holdings (MEDP) has reported Price to Sales for 11 consecutive years, with 20.9 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales rose 43.01% year-over-year to 20.9; the trailing twelve-month figure through Jun 2026 stood at 5.31 (up 34.49% YoY), and the FY2025 full-year result was 6.3, up 30.52% from the prior year.
• Price to Sales climbed to 20.9 in Q2 2026 per MEDP's latest filing, from 19.41 in the prior quarter.
• Across five years, Price to Sales topped out at 24.5 in Q1 2024 and bottomed at 12.74 in Q3 2022.
• Historically, Price to Sales has averaged 18.07 across 5 years, with a median of 17.84 in 2022.
• The sharpest annual moves came in 2022 and 2024: Price to Sales sank 44.66% in 2022, then soared 84.69% in 2024.
• Over 5 years, Price to Sales stood at 16.76 in 2022, then advanced by 12.86% to 18.91 in 2023, then gained by 0.27% to 18.97 in 2024, then advanced by 18.6% to 22.49 in 2025, then decreased by 7.09% to 20.9 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 20.9, 19.41, and 22.49 for Q2 2026, Q1 2026, and Q4 2025 respectively.